In yesterday’s Wall Street session, Outlook Therapeutics Inc (NASDAQ:OTLK) shares traded at $2.05, up 20.59% from the previous session.
OTLK stock price is now -61.84% away from the 50-day moving average and -71.76% away from the 200-day moving average. The market capitalization of the company currently stands at $58.47M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target maintained at $50, BTIG Research recently Upgraded its rating from Neutral to Buy for Outlook Therapeutics Inc (NASDAQ: OTLK). On February 15, 2024, Chardan Capital Markets Upgraded its previous ‘Neutral’ rating to ‘Buy’ on the stock keeping its target price maintained at $3, while ‘Guggenheim’ rates the stock as ‘Buy’
In other news, KENYON LAWRENCE A, Chief Financial Officer bought 5,000 shares of the company’s stock on Sep 26 ’24. The stock was bought for $28,446 at an average price of $5.69. Upon completion of the transaction, the Chief Financial Officer now directly owns 5,946 shares in the company, valued at $12189.3. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 28 ’24, Director Haddadin Yezan Munther bought 1,882 shares of the business’s stock. A total of $22,242 was incurred on buying the stock at an average price of $11.82. This leaves the insider owning 5,049 shares of the company worth $10350.45. A total of 35.60% of the company’s stock is owned by insiders.
During the past 12 months, Outlook Therapeutics Inc has had a low of $0.87 and a high of $12.85. The fifty day moving average price for OTLK is $5.3745 and a two-hundred day moving average price translates $7.261025 for the stock.
The latest earnings results from Outlook Therapeutics Inc (NASDAQ: OTLK) was released for 2024-06-30. The company reported revenue of $19.56 million for the quarter, compared to $18.14 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 7.84 percent.
